Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 research hub

Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

This study looks at combining two cancer drugs, tuvusertib and avelumab, for people with advanced Merkel cell skin cancer that hasn't responded to previous treatment. It aims to see if the combination works better than tuvusertib alone to stop the cancer from getting worse.